Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy
- PMID: 11232672
- DOI: 10.1111/j.1572-0241.2001.03515.x
Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy
Abstract
Objectives: Barrett's metaplasia is an acquired condition resulting from longstanding gastroesophageal reflux disease. Approximately 10% of esophagitis patients develop Barrett's esophagus. There is increasing evidence that duodenogastroesophageal reflux plays a role in the progression of disease. We further analyzed the correlation of acid and biliary reflux with reflux esophagitis and Barrett's esophagus and tested the effects of proton pump inhibitor therapy.
Methods: Patients with either reflux esophagitis (group 1) or Barrett's esophagus (group 2) prospectively underwent simultaneous 24-h esophageal pH and bile reflux testing without any therapy affecting acid secretion or GI motility. A total of 16 patients in group 1 and 18 patients in group 2 were tested again under proton pump inhibitor therapy.
Results: Acid and bile exposure were significantly increased in Barrett's patients (n = 23) compared to 20 esophagitis patients (median percentage of time that pH was <4 was 24.6% vs 12.4%, p = 0.01, median percentage of time that bilirubin absorbance was >0.2 was 34.7% vs 12.8%, p < 0.05). During therapy, both acid and bile reflux decreased significantly in both groups. Median percentage of time that pH was <4 and bilirubin absorbance was >0.2 before and during therapy was 18.2%/2.3% and 29.8%/0.7% (p = 0.001 and p = 0.001) in Barrett's esophagus patients versus 14.5%/3.6% and 21.5%/0.9% (p = 0.002 and p = 0.011) in esophagitis patients. There was no significant difference between the groups. In two esophagitis patients, bile reflux increased during therapy.
Conclusions: There is a good correlation of the duration of esophageal exposure to acid and bile with the severity of pathological change in the esophagus. Both acid and bile reflux is significantly suppressed by proton pump inhibitor therapy with exceptions among individual esophagitis patients. The prolonged simultaneous attack of bile and acid may play a key role in the development of Barrett's metaplasia.
Comment in
-
Timing of bile and acid reflux into the esophagus.Am J Gastroenterol. 2002 Jan;97(1):207. doi: 10.1111/j.1572-0241.2002.05407.x. Am J Gastroenterol. 2002. PMID: 11808955 No abstract available.
Similar articles
-
Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.Aliment Pharmacol Ther. 2004 Sep 15;20(6):637-43. doi: 10.1111/j.1365-2036.2004.02127.x. Aliment Pharmacol Ther. 2004. PMID: 15352912
-
Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication.J Gastrointest Surg. 1998 Jul-Aug;2(4):333-41. doi: 10.1016/s1091-255x(98)80072-3. J Gastrointest Surg. 1998. PMID: 9841990
-
24-h pH monitoring is necessary to assess acid reflux suppression in patients with Barrett's oesophagus undergoing treatment with proton pump inhibitors.Br J Surg. 1999 Nov;86(11):1472-4. doi: 10.1046/j.1365-2168.1999.01273.x. Br J Surg. 1999. PMID: 10583299
-
Total acid suppression and its effect on Barrett's esophagus.Am J Manag Care. 2000 Oct;6(16 Suppl):S895-8. Am J Manag Care. 2000. PMID: 11184662 Review.
-
Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?Dig Dis. 2014;32(1-2):156-63. doi: 10.1159/000357184. Epub 2014 Feb 28. Dig Dis. 2014. PMID: 24603402 Review.
Cited by
-
Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries.JAMA Oncol. 2018 Nov 1;4(11):1576-1582. doi: 10.1001/jamaoncol.2018.3054. JAMA Oncol. 2018. Retraction in: JAMA Oncol. 2019 May 1;5(5):744-745. doi: 10.1001/jamaoncol.2019.0653. PMID: 30422249 Free PMC article. Retracted.
-
Increased prevalence of gallstone disease and impaired gallbladder motility in patients with Barrett's esophagus.Dig Dis Sci. 2008 Aug;53(8):2268-75. doi: 10.1007/s10620-007-0126-5. Epub 2007 Dec 14. Dig Dis Sci. 2008. PMID: 18080764
-
Correlation of the location of superficial Barrett's esophageal adenocarcinoma (s-BEA) with the direction of gastroesophageal reflux.Endosc Int Open. 2016 May;4(5):E515-20. doi: 10.1055/s-0042-101757. Epub 2016 Apr 8. Endosc Int Open. 2016. PMID: 27227107 Free PMC article.
-
Multilayered epithelium may be found in patients with Barrett's epithelium and dysplasia or adenocarcinoma.Dig Dis Sci. 2006 Oct;51(10):1783-90. doi: 10.1007/s10620-006-9243-9. Dig Dis Sci. 2006. PMID: 16967312
-
A novel mechanism of acid and bile acid-induced DNA damage involving Na+/H+ exchanger: implication for Barrett's oesophagus.Gut. 2010 Dec;59(12):1606-16. doi: 10.1136/gut.2010.213686. Epub 2010 Sep 28. Gut. 2010. PMID: 20876775 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources